Myriad Genetics, Inc. $MYGN Shares Sold by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. sold 56,316 shares of Myriad Genetics, reducing its holdings by 7.3% in the first quarter, now owning 714,095 shares valued at approximately $6.33 million.
• Myriad Genetics' stock is currently down 5.7% with a market capitalization of $673.65 million and a trading price of $7.24, amidst varying price targets from analysts.
• A significant majority of the company’s shares, about 99.02%, are owned by institutional investors, indicating strong institutional confidence in the stock.

Goldman Sachs Group Inc. decreased its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 7.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 714,095 shares of the company's stock after selling 56,316 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.77% of Myriad Genetics worth $6,334,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of MYGN. Nuveen LLC acquired a new position in shares of Myriad Genetics in the first quarter worth about $10,437,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Myriad Genetics by 67.8% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 921,911 shares of the company's stock worth $8,177,000 after acquiring an additional 372,455 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Myriad Genetics by 278.9% in the first quarter. AQR Capital Management LLC now owns 433,392 shares of the company's stock worth $3,844,000 after acquiring an additional 319,007 shares in the last quarter. Jane Street Group LLC raised its stake in Myriad Genetics by 1,076.9% during the first quarter. Jane Street Group LLC now owns 213,826 shares of the company's stock valued at $1,897,000 after buying an additional 195,658 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in Myriad Genetics during the first quarter valued at approximately $1,655,000. Institutional investors and hedge funds own 99.02% of the company's stock.

Myriad Genetics Trading Up 1.2%

NASDAQ MYGN traded up $0.10 on Friday, hitting $7.78. 371,861 shares of the stock traded hands, compared to its average volume of 1,710,541. The stock has a 50-day moving average of $5.73 and a 200 day moving average of $6.39. Myriad Genetics, Inc. has a twelve month low of $3.76 and a twelve month high of $28.15. The company has a market capitalization of $723.39 million, a P/E ratio of -1.82 and a beta of 1.93.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.